PSA density

(redirected from PSAD)
Also found in: Acronyms.

PSA density

The relationship of the prostate specific antigen level to the size and weight (volume) of the prostate.

PSA density

Prostate-specific antigen density. A triggering factor for assessing PSA levels, by factoring transrectal ultrasonography (TRUS) into the decision to refer a patient for a prostate biopsy. While PSAD reduces biopsies, ultrasonographers may under- or over-read the images.
References in periodicals archive ?
Fitch conducted a review of a small targeted sample of PSAD's origination files and found the information contained in the reviewed files to be adequately consistent with the originator's policies and practices and the other information provided to the agency about the asset portfolio.
Medical records and pathological reports were reviewed regarding age, the levels of the PSA and PSAD, the prostate volume, histopathological findings, the Gleason score (the most common histopathological grading system for prostate cancer) of the 14 core biopsies, and the extension of the disease (defined as unilateral or bilateral involvement).
In this study, a new parameter named as PSAD variation rate (PSADVR), which indicated the rate of change of PSAD over 6 months, was presented and evaluated on predictability for guiding second biopsies in Chinese patients.
Mean age, FBG, PSA, PV, PSAD, and PSAR are shown for BMI groups (normal range, overweight, and obese) by age ([less than or equal to] 40, 41-59, and 60-85 years) in Table 2.
METHODS OF DATA ANALYSIS: Collected data was analysed with descriptive statistics followed by Chi-square test and Pearson's Correlation was used to analyse the association and comparison between PSAD and Histopathological reports respectively.
* Step (iv): If the partially estimated value of PSAD>[T.sub.DESS], then stop accumulating PSAD for further groups and proceed to the next candidate block in the search area.
Serum total PSA levels were divided by prostate volume to give PSA density (PSAD).
The principle aims of this study were to record the differences in outcome between smaller <75 g and larger [greater than or equal to] 75 g prostates and to test the hypothesis that PSAD is superior to PSA in determining the outcome of RALP for prostate cancer.
shows that PCA3 score is associated not only with the clinical stage, Gleason score, but also with clinically significant versus indolent prostate cancer (cT1c, PSAD < 0.15 ng/mL, Gleason score 6 and less, positive cores <33%).
PSA duzeyi, PSAD, klinik evre, Gleason skoru, tumorlu kor sayisi, tumorlu korda tumorun korda tumorun uzunlugu ve tumor klinik anlamli ve anlamsiz kanserlerin ayiriminda arastirilmis parametrelerdir.